Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Up 22.7% in November

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 386,500 shares, a growth of 22.7% from the November 15th total of 315,000 shares. Currently, 5.1% of the shares of the company are sold short. Based on an average daily volume of 3,150,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Trading of Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC purchased a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 32.23% of the company’s stock.

Analysts Set New Price Targets

Separately, Maxim Group restated a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Virpax Pharmaceuticals Price Performance

Shares of VRPX stock opened at $0.40 on Monday. Virpax Pharmaceuticals has a fifty-two week low of $0.29 and a fifty-two week high of $5.48. The stock’s 50-day simple moving average is $0.56 and its 200-day simple moving average is $0.77.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.